Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.50 Analyst target: $7.00 Upside: 1312.71%
Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.